Skip to main content
Top
Published in: Annals of Surgical Oncology 1/2021

Open Access 01-01-2021 | Metastasis | Peritoneal Surface Malignancy

Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction

Authors: Violante Di Donato, MD, PhD, Andrea Giannini, MD, Ottavia D’Oria, MD, Michele Carlo Schiavi, MD, PhD, Anna Di Pinto, MD, Margherita Fischetti, MD, PhD, Francesca Lecce, MD, Giorgia Perniola, MD, PhD, Francesco Battaglia, MD, Pasquale Berloco, MD, Ludovico Muzii, MD, Pierluigi Benedetti Panici, MD

Published in: Annals of Surgical Oncology | Issue 1/2021

Login to get access

Abstract

Objective

The purpose of this study was to evaluate the feasibility and safety in terms of prognostic significance and perioperative morbidity and mortality of cytoreduction in patients affected by advance ovarian cancer and hepato-biliary metastasis.

Methods

Patients with a least one hepatobiliary metastasis who have undergone surgical treatment with curative intent of were considered for the study. Perioperative complications were evaluated and graded with Accordion severity Classification. Five-year PFS and OS were estimated using the Kaplan–Meier curve.

Results

Sixty-seven (20.9%) patients had at least one metastasis to the liver, biliary tract, or porta hepatis. Forty-four (65.7%) and 23 (34.3%) patients underwent respectively high and intermediate complexity surgery according. Complete cytoreduction was achieved in 48 (71.6%) patients with hepato-biliary disease. In two patients (2.9%) severe complications related to hepatobiliary surgery were reported. The median PFS for the patients with hepato-biliary involvement (RT = 0 vs. RT > 0) was 19 months [95% confidence interval (CI) 16.2–21.8] and 8 months (95% CI 6.1–9.9). The median OS for the patients with hepato-biliary involvement (RT = 0 vs. RT > 0) 45 months (95% CI 21.2–68.8 months) and 23 months (95% CI 13.9–32.03).

Conclusions

Hepatobiliary involvement is often associated with high tumor load and could require high complex multivisceral surgery. In selected patients complete cytoreduction could offer survival benefits. Morbidity related to hepatobiliary procedures is acceptable. Careful evaluation of patients and multidisciplinary approach in referral centers is mandatory.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 (Version 1.2), Cancer Incidence and Mortality Worldwide, Lyon, France, International Agency for Research on Cancer, 2010. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 (Version 1.2), Cancer Incidence and Mortality Worldwide, Lyon, France, International Agency for Research on Cancer, 2010.
2.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRef Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRef
4.
go back to reference Cancer Statistics Center, American Cancer Society, cancerstatisticscenter.otg. The ASCO Post August 2019. Cancer Statistics Center, American Cancer Society, cancerstatisticscenter.otg. The ASCO Post August 2019.
5.
go back to reference Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monts FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRef Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monts FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRef
6.
go back to reference Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.CrossRef Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31.CrossRef
7.
go back to reference Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2013;90:390–6.CrossRef Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2013;90:390–6.CrossRef
8.
go back to reference Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77–85.CrossRef Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107:77–85.CrossRef
10.
go back to reference Kuhn W, Glorack G, Roder J, Schmalfeldt B, Pache L, Rust M, et al. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and IV. Int J Gynecol Cancer. 1998;8:56–63. Kuhn W, Glorack G, Roder J, Schmalfeldt B, Pache L, Rust M, et al. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and IV. Int J Gynecol Cancer. 1998;8:56–63.
11.
go back to reference Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003;89:16–21.CrossRef Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003;89:16–21.CrossRef
14.
go back to reference Aletti GD, Dowdy SC, Podratz KC, Cliby WA, Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1–7.CrossRef Aletti GD, Dowdy SC, Podratz KC, Cliby WA, Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1–7.CrossRef
16.
go back to reference Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):278–87.CrossRef Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72(3):278–87.CrossRef
18.
go back to reference Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma. An autopsy study. Epub 2011 Feb 3. Cancer. 1989;63(5):935–8.CrossRef Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma. An autopsy study. Epub 2011 Feb 3. Cancer. 1989;63(5):935–8.CrossRef
20.
go back to reference Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94(3):650–4.CrossRef Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94(3):650–4.CrossRef
21.
go back to reference Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Epub 2013 Feb 4. Gynecol Oncol. 2006;103(3):1083–90. Epub 2006 Aug 4.CrossRef Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Epub 2013 Feb 4. Gynecol Oncol. 2006;103(3):1083–90. Epub 2006 Aug 4.CrossRef
22.
go back to reference Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, Gardner GJ, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010;119(1):38–42. https://doi.org/10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.CrossRefPubMed Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, Gardner GJ, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010;119(1):38–42. https://​doi.​org/​10.​1016/​j.​ygyno.​2010.​05.​031. Epub 2010 Jul 6.CrossRefPubMed
24.
go back to reference Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol. 2013;130(3):487–92. https://doi.org/10.1016/j.ygyno.2013.06.017. Epub 2013 Jun 17.CrossRefPubMed Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol. 2013;130(3):487–92. https://​doi.​org/​10.​1016/​j.​ygyno.​2013.​06.​017. Epub 2013 Jun 17.CrossRefPubMed
30.
go back to reference Yoon SS, Jarnagin WR, Fong Y, DeMatteo RP, Barakat RR, Blumgart LH, Chi DS. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol. 2003;91(2):383–8.CrossRef Yoon SS, Jarnagin WR, Fong Y, DeMatteo RP, Barakat RR, Blumgart LH, Chi DS. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol. 2003;91(2):383–8.CrossRef
33.
go back to reference Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G et al. Trends in mortality after primary cytoreductive surgery for ovarian cancer: a systematic review and metaregression of randomized clinical trials and observational studies. Ann Surg Oncol. 2017;24(6):1688–97. https://doi.org/10.1245/s10434-016-5680-7. Epub 2016 Nov 28. Review.CrossRefPubMed Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G et al. Trends in mortality after primary cytoreductive surgery for ovarian cancer: a systematic review and metaregression of randomized clinical trials and observational studies. Ann Surg Oncol. 2017;24(6):1688–97. https://​doi.​org/​10.​1245/​s10434-016-5680-7. Epub 2016 Nov 28. Review.CrossRefPubMed
34.
go back to reference Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7.CrossRef Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7.CrossRef
35.
go back to reference Langstraat C, Aletti GD, Cliby WA. Morbidity, mortality, and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol. 2011;123:187–91.CrossRef Langstraat C, Aletti GD, Cliby WA. Morbidity, mortality, and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization. Gynecol Oncol. 2011;123:187–91.CrossRef
36.
go back to reference Di Donato V, Bardhi E, Tramontano L, Capomacchia FM, et al. Management of morbidity associated with pancreatic resection during cytoreductive surgery for epithelial ovarian cancer: a systematic review. Eur J Surg Oncol. 2020;46:694–702.CrossRef Di Donato V, Bardhi E, Tramontano L, Capomacchia FM, et al. Management of morbidity associated with pancreatic resection during cytoreductive surgery for epithelial ovarian cancer: a systematic review. Eur J Surg Oncol. 2020;46:694–702.CrossRef
37.
go back to reference Kahl A, du Bois A, Harter P, Prader S, Schneider S, Heitz F, et al. Prognostic value of the age-adjusted Charlson Comorbidity Index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Kahl A, du Bois A, Harter P, Prader S, Schneider S, Heitz F, et al. Prognostic value of the age-adjusted Charlson Comorbidity Index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer.
Metadata
Title
Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction
Authors
Violante Di Donato, MD, PhD
Andrea Giannini, MD
Ottavia D’Oria, MD
Michele Carlo Schiavi, MD, PhD
Anna Di Pinto, MD
Margherita Fischetti, MD, PhD
Francesca Lecce, MD
Giorgia Perniola, MD, PhD
Francesco Battaglia, MD
Pasquale Berloco, MD
Ludovico Muzii, MD
Pierluigi Benedetti Panici, MD
Publication date
01-01-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 1/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08989-3

Other articles of this Issue 1/2021

Annals of Surgical Oncology 1/2021 Go to the issue